According to the brokerage, Symbiotec Pharmalab has evolved from a steroidal API manufacturer into an integrated platform spanning active pharmaceutical ingredients (APIs), fermentation-led CDMO, and complex injectables, backed by manufacturing investments and backward integration.
NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Motilal Oswal has initiated coverage on Symbiotec Pharmalab Ltd. with a 'Buy' rating implying a potential upside of 23% from the reports market price. The brokerage valued Symbiotic at 35 times 12 months forward earnings, in-line to the sector price/earning of ~36 times to arrive at a target price of Rs 1,430, factoring in the company's established API base and earnings potential from the newer businesses.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
According to the brokerage, Symbiotec Pharmalab has evolved from a steroidal API manufacturer into an integrated platform spanning active pharmaceutical ingredients (APIs), fermentation-led CDMO, and complex injectables, backed by manufacturing investments and backward integration.
A leading corticosteroid/hormone API supplier (total addressable market: $800 million), Symbiotec is expanding into fermentation-based and high-value complex APIs (TAM: $92 billion; 10.4% CAGR over CY24–29).
ALSO READ | CG Power Shares May Rally 40% After Q2 Results; Motilal Oswal Raises Target Price On Strong Order Inflows
Symbiotec is already on a path to provide chemistry- and fermentation-based capabilities and capacity as a contract development manufacturing organicsation platform in precision fermentation, industrial biotechnology, and biologics, targeting a TAM of $50 billion.
Key risks
- High dependence on APIs and a concentrated product portfolio;
- delays in scaling CDMO, biologics, and complex injectables;
- geographical concentration of manufacturing facilities; and
- intensifying competition
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
